K
Kristin N. Adams
Researcher at Seattle Children's Research Institute
Publications - 17
Citations - 1489
Kristin N. Adams is an academic researcher from Seattle Children's Research Institute. The author has contributed to research in topics: Mycobacterium tuberculosis & Efflux. The author has an hindex of 9, co-authored 15 publications receiving 1190 citations. Previous affiliations of Kristin N. Adams include Seattle Children's & University of Washington.
Papers
More filters
Journal ArticleDOI
Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism.
Kristin N. Adams,Kevin K. Takaki,Lynn E. Connolly,Heather Wiedenhoft,Kathryn Winglee,Olivier Humbert,Paul H. Edelstein,Christine L. Cosma,Lalita Ramakrishnan +8 more
TL;DR: The existence of multidrug-tolerant organisms that arise within days of infection, are enriched in the replicating intracellular population, and are amplified and disseminated by the tuberculous granuloma are described.
Journal ArticleDOI
Alveolar Macrophages Provide an Early Mycobacterium tuberculosis Niche and Initiate Dissemination
Sara B. Cohen,Benjamin H. Gern,Jared L. Delahaye,Kristin N. Adams,Courtney R. Plumlee,Jessica K. Winkler,David R. Sherman,Michael Y. Gerner,Kevin B. Urdahl,Kevin B. Urdahl +9 more
TL;DR: It is revealed that early, productive Mtb infection occurs almost exclusively within airway-resident alveolar macrophages, and interleukin-1-mediated crosstalk between Mtb-infected AM and non-hematopoietic cells promotes pulmonary MtB infection by enabling infected cells to disseminate from the alveoli to the lung interstitium.
Journal ArticleDOI
Verapamil, and Its Metabolite Norverapamil, Inhibit Macrophage-induced, Bacterial Efflux Pump-mediated Tolerance to Multiple Anti-tubercular Drugs
TL;DR: This study infected the human macrophage-like cell line THP-1 with drug-sensitive and drug-resistant M. tuberculosis strains and found that tolerance developed to most antituberculosis drugs, including the newer agents moxifloxacin, PA-824, linezolid, and bedaquiline.
Journal ArticleDOI
Unique Lipid A Modifications in Pseudomonas aeruginosa Isolated from the Airways of Patients with Cystic Fibrosis
Robert K. Ernst,Samuel M. Moskowitz,Julia Emerson,Gretchen M. Kraig,Kristin N. Adams,Megan D. Harvey,Bonnie W. Ramsey,David P. Speert,Jane L. Burns,Samuel I. Miller +9 more
TL;DR: Results indicate that unique lipid A modifications occur in clinical P. aeruginosa CF isolates and none of the isolates from the environment or from patients with other conditions displayed these modifications.
Journal ArticleDOI
The Pseudomonas aeruginosa Lipid A Deacylase: Selection for Expression and Loss within the Cystic Fibrosis Airway
Robert K. Ernst,Kristin N. Adams,Samuel M. Moskowitz,Gretchen M. Kraig,Kiyoshi Kawasaki,Christopher M. Stead,M. Stephen Trent,Samuel I. Miller +7 more
TL;DR: Increased expression of the P. aeruginosa lipid A 3-O-deacylase (PagL) in isolates from CF infants compared to that in environmental isolates is demonstrated, suggesting that loss of PagL function can occur during long-term adaptation to the CF airway.